View our masking and visitation guidelines based on current rates of respiratory illnesses in the community.

Our new building on the hospital campus, Forest B, is open. Families and visitors can park in the new Forest B garage next to Emergency.

Clinical Trial Search block Test

COPPER HISTIDINATE TREATMENT FOR MENKES DISEASE

CYP-001

Phase: N/A
Clinicaltrials.gov ID: NCT04074512

What is the goal of the study?

This study investigates the clinical effects and safety of subcutaneous Copper Histidinate treatment for patients diagnosed with Menkes disease and previously treated at NICHD under protocol 09-CH-0059 and newly diagnosed Menkes disease patients.

Who can participate in the study?

Everyone

Study Team:

PI (Study Doctor): Terry Kho
Study Team Member: Hayden Vreugdenhil, hayden.vreugdenhil@seattlechildrens.org